Short review of SEC, a potential dexamethasone-sparing regimen for glioblastoma: Spironolactone, ecallantide, clotrimazole
- 1 September 2021
- journal article
- research article
- Published by Elsevier BV in Neurochirurgie
- Vol. 67 (5), 508-515
- https://doi.org/10.1016/j.neuchi.2020.12.008
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomasActa Neurochirurgica, 2012
- Why dapsone stops seizures and may stop neutrophils’ delivery of VEGF to glioblastomaBritish Journal Of Neurosurgery, 2012
- Clotrimazole Preferentially Inhibits Human Breast Cancer Cell Proliferation, Viability and GlycolysisPLOS ONE, 2012
- Corticosteroids in brain cancer patients: benefits and pitfallsExpert Review of Clinical Pharmacology, 2011
- Mineralocorticoid and Epidermal Growth Factor ReceptorsHypertension, 2011
- Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimagingBrain Tumor Pathology, 2010
- Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma?European Journal of Neurology, 2009
- Selective intermediate‐/small‐conductance calcium‐activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematomaEuropean Journal of Neuroscience, 2004
- Mechanism of the antimineralocorticoid effects of spirolactonesKidney International, 1981
- ClotrimazoleDrugs, 1975